414 related articles for article (PubMed ID: 22333315)
1. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
Bronger H; Kraeft S; Schwarz-Boeger U; Cerny C; Stöckel A; Avril S; Kiechle M; Schmitt M
Breast Cancer Res; 2012 Feb; 14(1):R30. PubMed ID: 22333315
[TBL] [Abstract][Full Text] [Related]
2. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.
Bronger H; Singer J; Windmüller C; Reuning U; Zech D; Delbridge C; Dorn J; Kiechle M; Schmalfeldt B; Schmitt M; Avril S
Br J Cancer; 2016 Aug; 115(5):553-63. PubMed ID: 27490802
[TBL] [Abstract][Full Text] [Related]
3. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.
Dengel LT; Norrod AG; Gregory BL; Clancy-Thompson E; Burdick MD; Strieter RM; Slingluff CL; Mullins DW
J Immunother; 2010; 33(9):965-74. PubMed ID: 20948440
[TBL] [Abstract][Full Text] [Related]
4. Heparins modulate the IFN-γ-induced production of chemokines in human breast cancer cells.
Fluhr H; Seitz T; Zygmunt M
Breast Cancer Res Treat; 2013 Jan; 137(1):109-18. PubMed ID: 23160925
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease.
Kundu N; Walser TC; Ma X; Fulton AM
Cancer Immunol Immunother; 2005 Oct; 54(10):981-7. PubMed ID: 15891886
[TBL] [Abstract][Full Text] [Related]
6. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.
Sugimoto T; Bartholomeusz C; Tari AM; Ueno NT
Breast Cancer Res; 2007; 9(4):R41. PubMed ID: 17612393
[TBL] [Abstract][Full Text] [Related]
8. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production.
Whiting D; Hsieh G; Yun JJ; Banerji A; Yao W; Fishbein MC; Belperio J; Strieter RM; Bonavida B; Ardehali A
J Immunol; 2004 Jun; 172(12):7417-24. PubMed ID: 15187119
[TBL] [Abstract][Full Text] [Related]
9. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
Timoshenko AV; Xu G; Chakrabarti S; Lala PK; Chakraborty C
Exp Cell Res; 2003 Oct; 289(2):265-74. PubMed ID: 14499627
[TBL] [Abstract][Full Text] [Related]
10. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
Karin N
Front Immunol; 2020; 11():976. PubMed ID: 32547545
[TBL] [Abstract][Full Text] [Related]
11. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
12. TNFα-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines.
Shin SY; Nam JS; Lim Y; Lee YH
J Biol Chem; 2010 Oct; 285(40):30731-40. PubMed ID: 20650898
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M
J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of cyclooxygenase-2 inhibitor celecoxib against toxicity of LPS-stimulated macrophages toward motor neurons.
Huang Y; Liu J; Wang LZ; Zhang WY; Zhu XZ
Acta Pharmacol Sin; 2005 Aug; 26(8):952-8. PubMed ID: 16038627
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
17. The role of CXCR3 and its ligands expression in Brucellar spondylitis.
Hu X; Shang X; Wang L; Fan J; Wang Y; Lv J; Nazierhan S; Wang H; Wang J; Ma X
BMC Immunol; 2020 Nov; 21(1):59. PubMed ID: 33208100
[TBL] [Abstract][Full Text] [Related]
18. CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors.
Rosenblum JM; Shimoda N; Schenk AD; Zhang H; Kish DD; Keslar K; Farber JM; Fairchild RL
J Immunol; 2010 Apr; 184(7):3450-60. PubMed ID: 20194716
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis.
Rozic JG; Chakraborty C; Lala PK
Int J Cancer; 2001 Aug; 93(4):497-506. PubMed ID: 11477553
[TBL] [Abstract][Full Text] [Related]
20. Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.
Wang X; Li G; Wang A; Zhang Z; Merchan JR; Halmos B
Mol Carcinog; 2013 Mar; 52(3):218-28. PubMed ID: 22121107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
